Grandeur Peak Global Advisors LLC reduced its position in shares of OrthoPediatrics Corp. (NASDAQ:KIDS – Free Report) by 47.0% in the second quarter, HoldingsChannel reports. The institutional investor owned 49,854 shares of the company’s stock after selling 44,236 shares during the quarter. Grandeur Peak Global Advisors LLC’s holdings in OrthoPediatrics were worth $954,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in OrthoPediatrics in the 2nd quarter worth $24,347,000. Millennium Management LLC boosted its holdings in shares of OrthoPediatrics by 48.0% during the fourth quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock worth $24,802,000 after purchasing an additional 452,840 shares during the period. AIGH Capital Management LLC purchased a new stake in shares of OrthoPediatrics during the second quarter worth about $5,161,000. Nantahala Capital Management LLC bought a new stake in shares of OrthoPediatrics in the second quarter worth about $4,636,002. Finally, AWM Investment Company Inc. bought a new stake in shares of OrthoPediatrics in the second quarter worth about $4,537,000. Hedge funds and other institutional investors own 69.05% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on KIDS shares. Piper Sandler reissued an “overweight” rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Truist Financial set a $22.00 price objective on OrthoPediatrics in a research report on Wednesday, August 5th. Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. TD Cowen restated a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Finally, BTIG Research increased their price objective on shares of OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, OrthoPediatrics has an average rating of “Moderate Buy” and an average target price of $26.44.
OrthoPediatrics Stock Performance
OrthoPediatrics stock opened at $23.65 on Monday. OrthoPediatrics Corp. has a 52-week low of $14.42 and a 52-week high of $26.74. The company has a market cap of $617.50 million, a P/E ratio of -14.08 and a beta of 0.98. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The business has a 50-day simple moving average of $21.41 and a two-hundred day simple moving average of $18.67.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. The firm had revenue of $70.51 million for the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. Analysts predict that OrthoPediatrics Corp. will post -1.14 EPS for the current year.
Insider Transactions at OrthoPediatrics
In related news, major shareholder Squadron Capital Llc sold 18,000 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $24.28, for a total value of $437,040.00. Following the transaction, the insider directly owned 6,863,464 shares of the company’s stock, valued at approximately $166,644,905.92. This trade represents a 0.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David R. Pelizzon sold 18,000 shares of OrthoPediatrics stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $24.28, for a total value of $437,040.00. Following the transaction, the director owned 6,863,464 shares in the company, valued at $166,644,905.92. This trade represents a 0.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 114,900 shares of company stock worth $2,829,906 in the last three months. Corporate insiders own 32.50% of the company’s stock.
OrthoPediatrics Profile
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
See Also
- Five stocks we like better than OrthoPediatrics
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Want to see what other hedge funds are holding KIDS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OrthoPediatrics Corp. (NASDAQ:KIDS – Free Report).
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
